Common Contracts
4 similar Underwriting Agreement contracts by Nexalin Technology, Inc., PDS Biotechnology Corp, PLX Pharma Inc.
NEXALIN TECHNOLOGY, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • September 16th, 2022 • Nexalin Technology, Inc. • Electromedical & electrotherapeutic apparatus • New York
Nexalin Technology, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell an aggregate of 2,315,000 units (the “Units”), with each Unit consisting of (a) one share of the Company’s common stock, $0.001 par value per share (the “Common Stock”), and (b) one warrant to purchase one share of Common Stock (the “Warrants”) (collectively, the “Firm Units”) to the several underwriters (such underwriters, for whom Maxim Group LLC (“Maxim” or the “Representative”) is acting as representative, the “Underwriters” and each an “Underwriter”). The Company has also agreed to grant to the Representative on behalf of the Underwriters an option (the “Option”) to purchase up to an additional 347,250 shares of Common Stock, representing fifteen percent (15%) of the shares of Common Stock sold as part of the Firm Units sold in the offering (the “Option Shares”), and/or 347,250 Warrants, representing fifteen percent (15%) of the Warrants
NEXALIN TECHNOLOGY, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • May 31st, 2022 • Nexalin Technology, Inc. • Electromedical & electrotherapeutic apparatus • New York
Nexalin Technology, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell an aggregate of [●] units (the “Units”), with each Unit consisting of (a) one share of the Company’s common stock $0.001 par value per share (the “Common Stock”) and (b) one Warrant (the “Warrants”) to purchase one share of Common Stock, (the “Firm Units”) to the several underwriters (such underwriters, for whom Maxim Group LLC (“Maxim” or the “Representative”) is acting as representative, the “Underwriters” and each an “Underwriter”). The Company has also agreed to grant to the Representative on behalf of the Underwriters an option (the “Option”) to purchase up to an additional [●] Units (the “Option Units”, and together with the Firm Units, the “Offered Securities”) on the terms set forth in Section 1(b) hereof. The offering of such Offered Securities is hereinafter called the “Offering”.
Underwriting AgreementUnderwriting Agreement • June 17th, 2021 • PDS Biotechnology Corp • Pharmaceutical preparations • New York
PDS Biotechnology Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 5,294,118 shares of its common stock, par value $0.00033 per share (the “Shares”). The 5,294,118 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 794,117 Shares. The Shares to be sold, if any, pursuant to such option are collectively called the “Option Shares”. The Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the “Offered Shares.” Cantor Fitzgerald & Co. (“Cantor”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on Schedule A, the term “Representative” as use
PLX PHARMA INC. UNDERWRITING AGREEMENTUnderwriting Agreement • October 5th, 2015 • PLX Pharma Inc. • Pharmaceutical preparations • New York
